Virtici
Virtici’s mission is to improve quality of life and save lives, and is primarily developing products to improve the way we treat cancer, autoimmunity, and cardiovascular/metabolic diseases.
Virtici’s mission is to improve quality of life and save lives, and is primarily developing products to improve the way we treat cancer, autoimmunity, and cardiovascular/metabolic diseases.
Allucent, formerly CATO SMS, is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.
Allucent, formerly CATO SMS, is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.
Allucent, formerly Nuventra, is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.
Azenta, formerly Brooks Automation & NEXUS, is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster.
Imaging Endpoints, an affiliate of Southwest Medical Imaging, specializes in developing and deploying optimal imaging in early-stage trials, advancing imaging analysis into late-stage trials, and supporting regulatory submissions.
Primrose Bio, formerly Pelican Expression and Primordial Genetics, is focused on developing and commercializing its integrated end-to-end technology platform for solving complex drug manufacturing and design challenges.
The Advanced Technology and Manufacturing Institute (ATAMI) is an open-access user facility with capabilities supporting both academic and industrial research and development. The ATAMI ecosystem creates synergy between academia and industry, and includes resources for business formation and funding. Research at ATAMI has origins in process intensification, and has evolved to include R&D of materials,…
PAI Life Science, formerly Protein Advances, specializes in the developmental and translational research necessary to bring products from the laboratory to bedside.
23andMe is a leading consumer genetics and research company. The mission of the company is to help people access, understand and benefit from the human genome. On Mar. 23, 2025, 23andMe Initiated Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process.
Molecular Knowledge Systems provides contract research services to assist clients in understanding how molecular structure and composition determine the physical properties of chemicals and at how physical properties can be manipulated to design improved chemical products.
A&G Pharmaceutical is a privately held theranostics company focused on the rapid development of monoclonal antibodies to disease-specific antigens as a basis for novel therapeutic and diagnostic products addressing a broad range of diseases.
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets.
3-D Matrix develops and manufactures a family of peptide biomaterials under the trade name PuraMatrix for use in clinical applications and life science research.
Puresyn is a technology company that develops, manufactures and markets products and services for separation and purification of nucleic acids and other biological molecules.
Allucent, formerly CATO SMS, is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.
Cellular Engineering Technologies (CET) specializes in stem cell research, tissue engineering and cancer biology.
ProteoGenex is an established innovative provider of human biological specimens and clinical information of the highest quality.
Virogenomics’ (VBD) mission is to identify, obtain, and develop rights to early-stage technologies for drug discovery and development.